c型凝集素样结构域家族2 (CLEC2D)促进乳腺癌的增殖和迁移,是一个不良预后因素。

IF 2.9
Mio Yamaguchi-Tanaka, Yui Kurihara, Kiyoshi Takagi, Ai Sato, Iori Yasuda, Yuto Yamazaki, Minoru Miyashita, Takashi Suzuki
{"title":"c型凝集素样结构域家族2 (CLEC2D)促进乳腺癌的增殖和迁移,是一个不良预后因素。","authors":"Mio Yamaguchi-Tanaka, Yui Kurihara, Kiyoshi Takagi, Ai Sato, Iori Yasuda, Yuto Yamazaki, Minoru Miyashita, Takashi Suzuki","doi":"10.1007/s12282-025-01777-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>C-type lectin-like domain family 2 (CLEC2D), a transmembrane protein, is a ligand for the inhibitory receptor CD161, which is expressed in several types of immune cells. CLEC2D expressed on cancer cells suppresses antitumor effect of these cells by interacting with CD161 in human malignancies. However, its clinical significance in breast cancer and its direct biological role in cancer cells remain largely unclear.</p><p><strong>Methods: </strong>In this study, we immunolocalized CLEC2D in 174 breast cancer tissues and correlated its immunoreactivity with clinicopathological parameters and clinical outcomes. Additionally, we conducted in vitro assays to examine the effects of CLEC2D on the proliferation and migration of breast cancer cell lines.</p><p><strong>Results: </strong>CLEC2D immunoreactivity was predominantly detected in the cytoplasm of breast cancer cells and was associated with increased proliferation and invasion, as well as poor clinical outcomes especially in those who had received chemotherapy. In vitro experiments demonstrated that the knockdown of CLEC2D significantly suppressed the proliferation and migration of MCF-7, MDA-MB-231, T-47D breast cancer cells.</p><p><strong>Conclusion: </strong>We therefore concluded that CLED2D directly promoted breast cancer cell proliferation and migration independently of immune cells and served as a poor prognostic factor in breast cancer.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"C-type lectin-like domain family 2 (CLEC2D) promotes proliferation and migration of breast cancer and serves as a poor prognostic factor.\",\"authors\":\"Mio Yamaguchi-Tanaka, Yui Kurihara, Kiyoshi Takagi, Ai Sato, Iori Yasuda, Yuto Yamazaki, Minoru Miyashita, Takashi Suzuki\",\"doi\":\"10.1007/s12282-025-01777-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>C-type lectin-like domain family 2 (CLEC2D), a transmembrane protein, is a ligand for the inhibitory receptor CD161, which is expressed in several types of immune cells. CLEC2D expressed on cancer cells suppresses antitumor effect of these cells by interacting with CD161 in human malignancies. However, its clinical significance in breast cancer and its direct biological role in cancer cells remain largely unclear.</p><p><strong>Methods: </strong>In this study, we immunolocalized CLEC2D in 174 breast cancer tissues and correlated its immunoreactivity with clinicopathological parameters and clinical outcomes. Additionally, we conducted in vitro assays to examine the effects of CLEC2D on the proliferation and migration of breast cancer cell lines.</p><p><strong>Results: </strong>CLEC2D immunoreactivity was predominantly detected in the cytoplasm of breast cancer cells and was associated with increased proliferation and invasion, as well as poor clinical outcomes especially in those who had received chemotherapy. In vitro experiments demonstrated that the knockdown of CLEC2D significantly suppressed the proliferation and migration of MCF-7, MDA-MB-231, T-47D breast cancer cells.</p><p><strong>Conclusion: </strong>We therefore concluded that CLED2D directly promoted breast cancer cell proliferation and migration independently of immune cells and served as a poor prognostic factor in breast cancer.</p>\",\"PeriodicalId\":520574,\"journal\":{\"name\":\"Breast cancer (Tokyo, Japan)\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast cancer (Tokyo, Japan)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12282-025-01777-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast cancer (Tokyo, Japan)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12282-025-01777-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:c型凝集素样结构域家族2 (CLEC2D)是一种跨膜蛋白,是抑制受体CD161的配体,在多种类型的免疫细胞中表达。在人类恶性肿瘤中,癌细胞上表达的cle2d通过与CD161相互作用抑制癌细胞的抗肿瘤作用。然而,其在乳腺癌中的临床意义及其在癌细胞中的直接生物学作用在很大程度上仍不清楚。方法:在本研究中,我们将CLEC2D免疫定位于174例乳腺癌组织,并将其免疫反应性与临床病理参数和临床结果相关联。此外,我们还进行了体外实验,以检验cle2d对乳腺癌细胞系增殖和迁移的影响。结果:CLEC2D免疫反应性主要存在于乳腺癌细胞的细胞质中,并与增殖和侵袭增加有关,临床结果较差,特别是在接受化疗的患者中。体外实验表明,CLEC2D敲低可显著抑制MCF-7、MDA-MB-231、T-47D乳腺癌细胞的增殖和迁移。结论:我们认为CLED2D可独立于免疫细胞直接促进乳腺癌细胞的增殖和迁移,是乳腺癌预后不良的因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
C-type lectin-like domain family 2 (CLEC2D) promotes proliferation and migration of breast cancer and serves as a poor prognostic factor.

Background: C-type lectin-like domain family 2 (CLEC2D), a transmembrane protein, is a ligand for the inhibitory receptor CD161, which is expressed in several types of immune cells. CLEC2D expressed on cancer cells suppresses antitumor effect of these cells by interacting with CD161 in human malignancies. However, its clinical significance in breast cancer and its direct biological role in cancer cells remain largely unclear.

Methods: In this study, we immunolocalized CLEC2D in 174 breast cancer tissues and correlated its immunoreactivity with clinicopathological parameters and clinical outcomes. Additionally, we conducted in vitro assays to examine the effects of CLEC2D on the proliferation and migration of breast cancer cell lines.

Results: CLEC2D immunoreactivity was predominantly detected in the cytoplasm of breast cancer cells and was associated with increased proliferation and invasion, as well as poor clinical outcomes especially in those who had received chemotherapy. In vitro experiments demonstrated that the knockdown of CLEC2D significantly suppressed the proliferation and migration of MCF-7, MDA-MB-231, T-47D breast cancer cells.

Conclusion: We therefore concluded that CLED2D directly promoted breast cancer cell proliferation and migration independently of immune cells and served as a poor prognostic factor in breast cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信